Biotest Aktiengesellschaft reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EUR 107.7 million compared to EUR 113.6 million a year ago. Net loss was EUR 14.3 million compared to EUR 10.1 million a year ago. Basic loss per share from continuing operations was EUR 0.37 compared to EUR 0.26 a year ago.
For the nine months, sales was EUR 360.8 million compared to EUR 371.4 million a year ago. Net loss was EUR 34.2 million compared to EUR 28.3 million a year ago. Basic loss per share from continuing operations was EUR 0.87 compared to EUR 0.73 a year ago.